$MRK Recent News Apple green ahead of earnings;

New Post Public Reply Private Reply Replies (0) Message Board

Jan 31, 2014 at 1:55 PM

$MRK Recent News

Apple green ahead of earnings; Caterpillar tops gainers 3:42 p.m. Jan. 27, 2014 - Saumya Vaishampayan
Technical damage inflicted, S&P’s trend turns lower 11:49 a.m. Jan. 27, 2014 - Michael Ashbaugh
Merck hits a new high as analyst sees opening for new cancer drug 11:16 a.m. Jan. 27, 2014 - blogs.marketwatch.com
Dow industrials suffer worst drop since Sept. 20: Stock market live blog recap 4:41 p.m. Jan. 13, 2014 - blogs.marketwatch.com
Beam up on Suntory deal; Elliott report lifts Juniper 4:17 p.m. Jan. 13, 2014 - Saumya Vaishampayan
Merck shares hit 52-week high on drug hopes, plans for cutbacks 12:31 p.m. Jan. 13, 2014 - blogs.marketwatch.com
Merck initiates melanoma filing with FDA 11:45 a.m. Jan. 13, 2014 - Tess Stynes
Merck shares rise 3%, best on Dow average 9:41 a.m. Jan. 13, 2014 - Laura Mandaro
Statin usefulness questioned, but patent expirations may ease pain 1:02 p.m. Jan. 8, 2014 - blogs.marketwatch.com
Cholesterol drugs: Do you need them, or not? 5:00 a.m. Jan. 8, 2014 - Elizabeth O'Brien
Buying the 2014 recovery 12:01 a.m. Jan. 7, 2014 - Jim Lowell
Merck, Twitter, Apple are stocks to watch 4:34 p.m. Dec. 29, 2013 - Wallace Witkowski
Merck to revamp its R&D practices: WSJ 4:49 p.m. Dec. 27, 2013 - Wallace Witkowski
Merck to radically reshape R&D unit: WSJ 4:40 p.m. Dec. 27, 2013 - Wallace Witkowski
Not all pharmaceuticals are created equal 12:39 p.m. Dec. 26, 2013 - The Trading Deck
EU approves Merck's Erbitux for cancer treatment 4:52 a.m. Dec. 23, 2013 - MarketWatch.com
Biotechs continue to pay off 10:27 a.m. Dec. 20, 2013 - The Trading Deck
Safe and steady ETFs for the new year 12:03 p.m. Dec. 9, 2013 - Jim Lowell
Merck, McDonald's are top decliners in Dow index 4:05 p.m. Dec. 4, 2013 - Polya Lesova
Cuts, stock buyback, acquisition combine to boost Forest shares 11:09 a.m. Dec. 2, 2013 - blogs.marketwatch.com

6 Reasons Why Bristol-Myers Is A Good Immuno-Oncology Investment For 2014 7:52 a.m. Today - Seeking Alpha
Merck Ends Use of Chimpanzees in Research 6:15 p.m. Jan. 30, 2014 - WSJ.com
AstraZeneca Ends Tropical-Disease Research 7:58 a.m. Jan. 30, 2014 - WSJ.com
5 Stocks Pulling The Drugs Industry Downward 12:02 p.m. Jan. 29, 2014 - TheStreet.com
An Option On Adoption Of A New Multiple Sclerosis Treatment 8:51 a.m. Jan. 29, 2014 - Seeking Alpha
Bayer's Aleve May Have Lower Cardiac Risk Than Rival Painkillers 7:20 p.m. Jan. 28, 2014 - WSJ.com
Stability With The 'Everyday American' Portfolio 12:04 p.m. Jan. 28, 2014 - Seeking Alpha
Questcor 57% January Upside Eclipsed Healthcare Dogs 9:36 a.m. Jan. 28, 2014 - Seeking Alpha
Pfizer: Bad Quarter, Good Year, Better Outlook 9:35 a.m. Jan. 28, 2014 - Wall St. Cheat Sheet
Will Recent Headlines Hurt Pfizer Stock? 8:29 a.m. Jan. 28, 2014 - Wall St. Cheat Sheet
'Fast Money' Recap: Getting to the Core of Apple 5:00 a.m. Jan. 28, 2014 - TheStreet.com
The Acquisition Of Mills Pharmaceuticals Put Another Arrow In The Quiver Of Galena 6:07 p.m. Jan. 27, 2014 - Seeking Alpha
Merck & Co Inc (MRK): Today's Featured Drugs Winner 5:00 p.m. Jan. 27, 2014 - TheStreet.com
Merck’s New Cancer Drug Boosts Its Rating 4:38 p.m. Jan. 27, 2014 - Wall St. Cheat Sheet
The 5 Stocks That Dominated the Market on Monday 3:35 p.m. Jan. 27, 2014 - 247WallSt.com
Update on Endocyte Candidates - Analyst Blog 1:30 p.m. Jan. 27, 2014 - Zacks.com
Merck +2.8% as Morgan Stanley sees opening for new cancer drug 12:32 p.m. Jan. 27, 2014 - Seeking Alpha
Interesting January 2016 Stock Options For MRK 12:01 p.m. Jan. 27, 2014 - TheStreet.com
Obamacare Boosts Health Funds 11:26 a.m. Jan. 27, 2014 - TheStreet.com
Dow Today: Merck (MRK) Higher 11:00 a.m. Jan. 27, 2014 - TheStreet.com

TechConnect, National Innovation, and SBIR/STTR Summit Announce Top Corporate Partners and Innovation Submission Deadline 10:30 a.m. Jan. 30, 2014 - PR Newswire - PRF
Critical Alerts For Advanced Micro Devices, Merck, Urban Outfitters, Peabody Energy, and TakeTwo Interactive Released By InvestorsObserver 9:31 a.m. Jan. 30, 2014 - PR Newswire - PRF
FDA Advisory Committee recommends approval of ragweed sublingual allergy immunotherapy tablet 3:02 p.m. Jan. 28, 2014 - GlobeNewswire
RXI Pharmaceuticals Could Benefit from Biotech Industry Dynamics 10:06 a.m. Jan. 24, 2014 - ACCESSWIRE
ALK announces posting of briefing documents for FDA Advisory Committee meeting on the ragweed sublingual tablet 8:05 a.m. Jan. 24, 2014 - GlobeNewswire
Formex CSO Blair West to Speak at 3rd Drug Formulation & Bioavailability Conference 10:00 a.m. Jan. 23, 2014 - PR Newswire - PRF
Pharmerging Markets 2012-2016 11:12 a.m. Jan. 22, 2014 - PR Newswire - PRF
John Daly, Previous Merck Exec., Offers Consulting Tips 6:35 p.m. Jan. 17, 2014 - Marketwire
Sanford Heisler Adds Four New Class Representatives To $250M Gender Discrimination Class Action Suit Against Pharma Giant Merck 10:03 a.m. Jan. 17, 2014 - PR Newswire - PRF
Trimel Announces Appointment of Tom Rossi to Its Board of Directors 5:08 p.m. Jan. 16, 2014 - Marketwire
Merck Statement on FDA Advisory Committee for Vorapaxar, Merck’s Investigational Antiplatelet Medicine 6:59 p.m. Jan. 15, 2014 - BusinessWire - BZX
Merck Provides Update on Accelerated Strategic Actions for Growth at 32nd Annual J.P. Morgan Healthcare Conference 8:35 a.m. Jan. 13, 2014 - BusinessWire - BZX
Merck Initiates Rolling Submission of U.S. Biologics License Application for MK-3475, an Investigational Anti-PD-1 Immunotherapy, in Patients with Advanced Melanoma 8:30 a.m. Jan. 13, 2014 - BusinessWire - BZX
Alnylam Acquires Investigational RNAi Therapeutic Assets from Merck 9:00 p.m. Jan. 12, 2014 - BusinessWire - BZX
Biotech Investing Strategies in 2014 Is Key Topic Bringing Investors to San Francisco for Biotech Showcase(TM) 2014 Next Week, January 13 10:59 a.m. Jan. 9, 2014 - BusinessWire
Dako to collaborate with Merck on development of companion diagnostics for cancer treatment 9:16 a.m. Jan. 9, 2014 - GlobeNewswire
Dako to collaborate with Merck on development of companion diagnostics for cancer treatment 9:00 a.m. Jan. 9, 2014 - Thomson Reuters ONE
Merck Receives FDA Approval for ISENTRESS(R) (raltegravir) for Pediatric Oral Suspension 8:29 a.m. Jan. 8, 2014 - BusinessWire
Health Care Sector Under the Lens: Pfizer, Merck & Co., AbbVie and Zogenix 8:00 a.m. Jan. 8, 2014 - PR Newswire
Presentation Schedules, Stock Movements, Agreements, and New Appointments - Research Report on Celgene, Merck, Bristol-Myers, Valeant, and Mylan 8:00 a.m. Jan. 7, 2014 - PR Newswire

Newer

Older

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Radiation Oncology Text Earns Doody's 2026 Nod

Recognition in Radiation Oncology In the rapidly advancing arena of radiation oncology, staying current is no small feat. But here's a feather in the cap of one publication doing just that: Fundamentals of Radiation Oncology: Physical, Biological, and Clinical Aspects, 4th Edition. This resource has made quite the splash by snagging a spot on the 2026 Doody's Core Titles...

Curis Prepares for Q3 2026 Results Amid Tough Sector Trends

All Eyes on Curis as Q3 Financials Loom Just when you think you’ve seen it all in this wild biotech ride, Curis, Inc. (NASDAQ: CRIS) is prepping to roll out their third quarter financial and operating results. Circle your calendars for November 12, 2026, because the clock’s ticking down to their 4:00 p.m. ET announcement, swiftly followed by a conference call at 4:30...

Home Insurance Depreciation and What it Means for You

A Deep Dive into Depreciation's Impact on Home Insurance Folks, if you haven't battled the insurance beast, you're missing out on an unholy mess. Let's talk about something that's been quietly gnawing at homeowners’ wallets—depreciation in home insurance claims. Peggy Schneider, an insurance guru from Kalispell, Montana, lays it all out in HelloNation, and I'm here to...

FDA Greenlights Halozyme's Cancer Treatment Breakthrough

FDA's Seal of Approval: A Game Changer Well, folks, here's a twist in the story of cancer treatment with FDA giving a nod to RYBREVANT FASPRO. Johnson & Johnson's latest offering, fueled by Halozyme's groundbreaking ENHANZE technology, just snagged accelerated approval. We're not just talking any old treatment here; it's a dual-targeted therapy for head and neck cancer...

Birth Registration Revolution: OSIA Interoperability Demo

Bringing Birth Registration into the 21st Century Alright, let's cut through the fog. If you ask most folks about their birth certificates, you'd hear tales of tattered paper and government office runs. What if I told you this vital piece of paper could be reborn altogether? That's what the Secure Identity Alliance is up to with their OSIA Live Interoperability Demo at...

TELUS Boosts Board with Strategic Executive Appointments

New Faces on the TELUS Board: Shaping the Future Alright, investors, here's the scoop straight from the trenches: TELUS (TSX:TU) is shaking things up at the top. Marc Allera and Bill Thomas are stepping into the fray as the newest members of the board, effective January 1, 2027. If you're not familiar with these names, it's time to tune in because they've got the chops to...

Encompass Health Faces Uncertain Future with Sea Pines

Unexpected Downpour Closes Sea Pines They say when it rains, it pours. That's not just true in life, but as it happens, it's quite literal in Melbourne, Florida. A deluge of biblical proportions forced an immediate lockdown of the Sea Pines Rehabilitation Hospital. Flooded to the gills, this once stalwart institution finds its doors shuttered indefinitely. It's a...

Bowling Makes a Strike at Macy's 100th Parade in NYC

Rolling with Tradition: Bowling at Macy's Parade Back in the day, bowling wasn't exactly the sport making headlines. But times, they change. Here we are in the thick of things, witnessing Go Bowling getting its moment in the spotlight during the historic 100th Macy's Thanksgiving Day Parade®. It's not about raking in the dough or hitting some stocks; it’s about...

PPL Reports Strong Q3; Long-Term EPS Growth Up

Solid Earnings in a Challenging Market Anytime you start hearing a company like PPL boasting about their quarterly earnings, it's time to sit up straight and pay attention. The utility giant didn’t just match expectations, they beat 'em, clocking in with $0.54 per share in ongoing earnings for Q3 2026, up from $0.48 the previous year. Not a bad step forward if you ask...

Tucows Shows Progress in Q3 2026 Amidst Net Loss

Q3 Snapshot: Balancing Act at Tucows Man, if there's one thing you can count on from Tucows, it's that they'll shuffle the deck just when you're getting comfortable. Here in the third quarter of 2026, they've managed a decent juggling act. Their unaudited numbers show consolidated net revenue ticking up 1.4% from last year, rounding out at a cool $100 million. That's...